Regeneron to start Phase 3 virus treatment trials

Monday, 06. July 2020 13:35

Regeneron Pharmaceuticals Inc. announced on Monday that Phase 3 trials of its "investigational double antibody cocktail" REGN-COV2's effectiveness in COVID-19 prevention will start in cooperation with the United States National Institute of Allergy and Infectious Diseases (NIAID). The trials will be carried out at around 100 sites and will include 2,000 patients in the US, the company noted.

Also, "two adaptive Phase 1/2/3 trials testing the cocktail's ability" to be used in treatment advanced to "the Phase 2/3 portion," Regeneron revealed, adding that 1,850 hospitalized and 1,050 non-hospitalized patients will participate in the treatment trials in the US, Brazil, Mexico and Chile.

"We are running simultaneous adaptive trials in order to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, even in the midst of an ongoing global pandemic," President and Chief Scientific Officer of Regeneron George D. Yancopoulos said in a statement.

Related Links: Regeneron Pharmaceuticals Inc.
Breaking the News / MS